Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
4 studies found for:    7910230 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Withdrawn A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Docetaxel, PSK®;   Drug: Docetaxel, Placebo
2 Unknown † Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients
Condition: Gastric Cancer
Interventions: Drug: Tegafur-gimeracil-oteracil potassium (TS-1);   Drug: Krestin (PSK)
3 Terminated Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
Condition: Gastric Cancer
Interventions: Drug: Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK);   Drug: Tegafur/gimeracil/oteracil potassium (S-1)
4 Completed Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK
Condition: Gastric Cancer
Interventions: Drug: Tegafur-gimeracil-oteracil potassium (TS-1);   Drug: Krestin (PSK)
To Top

† Indicates status has not been verified in more than two years